TABLE 1.

Characteristics of six patients with Desulfovibrio fairfieldensis bacteremia^a

Patient no.	Yr of report	Age (yr)	Sex	Past medical history	Source	Procedures	Antimicrobials	Recovery from other sites	Outcome	Reference
1	1997	75	M	SGNP, COAD, HTN, DVT, NOCL	BBAP	CLNSC	i.v. CIP, p.o. CIP	No	Recovery	11
2	2000	23	M	GU	P. Apdx	Apdct	i.v. FAM, i.v. MTZ	No	Recovery	9
3	2000	85	M	CCF, RF	RCTRG	No	NR	No	Recovery	9
4	2005	NR	NR	NR	NR	NR	NR	NR	NR	15
5	2007	77	M	DM2, CVA, HTN, CAD, CDL	BT	ERCP	i.v. TIM, p.o. CIP	No	Recovery	This study
6	1977	67	M	CP, SYN	BT	CHCYST	Nil	No	Recovery	13

^aApdct, appendectomy; BBAP, bleeding benign adenomatous polyps; BT, biliary tract; CAD, coronary artery disease; CCF, chronic cardiac failure; CDL, choledocholithiasis; CHCYST, cholecystectomy; CIP, ciprofloxacin; CLNSC, colonoscopy; COAD, chronic obstructive airway disease; CP, chest pain; CVA, cerebrovascular accident; DM2, type 2 diabetes mellitus; DVT, deep venous thrombosis; ERCP, endoscopic retrograde cholangiopancreatography; FAM, cefamandole; GU, gastric ulcer disease; HTN, hypertension; M, male; MTZ, metronidazole; NOCL, nonobstructive cholelithiasis; NR, not reported; P. Apdx, perforated appendix; p.o., oral administration; RCTRG, rectorrhagia; RF, renal failure; SGNP, sclerosing glomerulonephritis; SYN, syncope; TIM, ticarcillin-clavulanate.